Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.38 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.35 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 10/20 | 0.34 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 5/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25754647 | 0.88 | DPP8 (0.47) | DPP8L3MBTL3L3MBTL1CHRM1 | |
| SCHEMBL25754640 | 0.82 | POLB (0.41) | DPP8CHRM1 | |
| SCHEMBL25754634 | 0.72 | — | — | |
| SCHEMBL18347947 | 0.70 | CHRNB2 (0.50) | L3MBTL3L3MBTL1CHRM1 | |
| SCHEMBL17152543 | 0.69 | DPP8 (0.48) | DPP8DPP7L3MBTL3L3MBTL1DPP4 | |
| SCHEMBL3278347 | 0.68 | DPP8 (0.40) | DPP8DPP7DPP4CHRM1 | |
| SCHEMBL3282806 | 0.68 | DPP8 (0.40) | DPP8DPP7DPP4CHRM1 | |
| SCHEMBL13030971 | 0.67 | DPP7 (0.50) | DPP8DPP7L3MBTL3L3MBTL1DPP4 | |
| SCHEMBL3279072 | 0.66 | DPP4 (0.40) | DPP8DPP7L3MBTL3L3MBTL1DPP4 | |
| SCHEMBL7767132 | 0.66 | L3MBTL3 (0.46) | L3MBTL3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | UCHL3, UBE2L3, ADAM33 | DPP8 831/4885GRIK1 3680/4885GRIK2 3901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.